Compare AU

Compare CURE vs. FAIR

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Australian Sustainability Leaders ETF (FAIR). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

FAIR

Popularity

Low

Medium

Pearlers invested

80

1,109

Median incremental investment

$620.00

$758.52

Median investment frequency

Monthly

Monthly

Median total investment

$1,296.12

$1,612.50

Average age group

> 35

26 - 35


Key Summary

CURE

FAIR

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

The fund aims to track the performance of the NASDAQ FUTURE AUSTRALIAN SUSTAINABILITY LEADERS INDEX before considering fees, taxes, and other expenses.

Top 3 holdings

AbbVie Inc (2.62 %)

Alnylam Pharmaceuticals Inc (2.59 %)

Amgen Inc (2.59 %)

SPI 200 FUTURES MAR25 (0 %)

XERO LTD (4.48 %)

SUNCORP GROUP LTD (4.41 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Financials (16.82 %)

Health Care (16.52 %)

Real Estate (16.06 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (89.09 %)

New Zealand (6.19 %)

United States (4.72 %)

Management fee

0.45 %

0.49 %


Key Summary

CURE

FAIR

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Nasdaq Future Australian Sustainability Leaders Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.49 %

Price

$48.91

$21.64

Size

$36.111 million

$1.160 billion

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

3.37 %

Market

ASX

ASX

First listed date

12/11/2018

29/11/2017

Purchase fee

$6.50

$6.50


Community Stats

CURE

FAIR

Popularity

Low

Medium

Pearlers invested

80

1,109

Median incremental investment

$620.00

$758.52

Median investment frequency

Monthly

Monthly

Median total investment

$1,296.12

$1,612.50

Average age group

> 35

26 - 35


Pros and Cons

CURE

FAIR

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to AU market

  • Higher price growth

Cons

  • Lower exposure to AU market

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

FAIR

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home